RAC 1.11% $1.83 race oncology ltd

There is a plethora of information around why drugs fail and...

  1. 125 Posts.
    lightbulb Created with Sketch. 33
    There is a plethora of information around why drugs fail and successful drug repurposing. Indeed even Keytruda was close to being sold off before it was commercialized. Bisantrene story was that its original formulation (RC110) meant a more invasive treatment with a smaller market and for internal reasons post being acquired, Lederle chose between their pipeline oncology drugs and commercialized another. Not that Bisantrene did not work as the studies from the period showed. The new formulation has greater commercial appeal if successful.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.83
Change
0.020(1.11%)
Mkt cap ! $310.8M
Open High Low Value Volume
$1.81 $1.83 $1.79 $142.0K 78.77K

Buyers (Bids)

No. Vol. Price($)
1 500 $1.81
 

Sellers (Offers)

Price($) Vol. No.
$1.83 641 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.